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Introduction
1,2-Dibromoethane (ethylene dibromide, EDB,
ethylene bromide, CAS No. 106-93-4), a colorless
volatile liquid, enjoys considerable use as a lead
scavengerin leaded gasolines and as a soiland grain
fumigant, mainly as a nematocide. The use of
1,2-dibromoethane as a fuel additive appears to be
decreasing as leaded gasoline for automobiles is
apparently being phased downward. Yet, more
than 100 formulated pesticides contain EDB. In
1977, 120 million kilograms were produced in the
United States. Lesser uses include as a dye inter-
mediate, an industrial solvent (for resins, gums,
waxes), and in some fire extinguishers.
1,2-Dibromoethane affects livermicrosomes, DNA,
and sperm. Human exposure to EDB can cause
eye, skin and respiratory irritation as well as
damage to the liver, kidney, spleen, and lungs.
Ethylene dibromide was mutagenic for Salmo-
nella typhimurium G46, TA 1530 and TA 1535
without metabolic activation (1,2), for Drosophila
melanogaster (3) and for Tradescantia (4).
By the gavage route of administration, 1,2-
dibromoethane was carcinogenic for Osborne-
Mendel rats, causing squamous cell carcinomas of
the forestomach in both sexes, hepatocellular carci-
nomas in females, and hemangiosarcomas of the
circulatory system in males. EDB was carcinogenic
in B6C3F1 mice, causing squamous cell carcinomas
of the forestomach and alveolar/bronchiolar adeno-
mas in both sexes (5-9). These lesions were seen as
early as week 12 in rats and week 24 in mice.
1,2-Dibromoethane was tested again by the
National Toxicology Program/National Cancer In-
stitute (NTP/NCI) Bioassay Program, this time
using inhalation exposure to determine the effects
by this route because workers and the general
population are exposed to airborne EDB.
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Methods
Male and female inbred Fischer344rats and male
and female hybrid B6C3F1 mice, obtained from the
Frederick Cancer Research Center, were used in
this study. Control and treated groups contained 50
animals ofeach sex and species. Allgroups received
Wayne Lab Blox and water ad libitum (except food
was removed during exposure periods). Chamber
control and treated groups were exposed to concen-
trations of0, 10, or 40 ppm EDB for 6 hr per day, 5
days per week, for 78 to 103 weeks.
The 1,2-dibromoethane used in this inhalation
study was > 99% pure. This carcinogenesis bioas-
say was conducted from July 1976 to July 1978 at
Hazleton Laboratories, America, Inc., under a
subcontract to Tracor Jitco (prime contractor for
the testing program).
All animals that died during the study or that
were killed at the end ofthe exposure period were
subjected to a gross necropsy and a complete
histopathological examination. Statistical analyses
of survival differences among groups were done
using life table methods (10,11). For tumor inci-
dence data, pairwise comparisons were made by
Fisher's exact tests, and the significance of dose-
responsetrendswasassessedbyCochran-Armitage
tests (12,13). The study design conformed to the
NCIGuidelinesforCarcinogenBioassays inSmall
Rodents (14).
Results
Throughout the study, mean body weights of
high dose rats andhigh dose mice ofeither sex were
lower than those of the corresponding untreated
controls. Survival ofthe high dose rats ofeither sex
and of the low and high dose female mice was
significantly shorter than that in the corresponding
controls.
In male rats, 38/50 (76%) ofthe control group and
35/50 (70%) ofthe low dose group lived to the end of
the study at 104-106 weeks. The high dose group
was killed at week 89, at which time 5/50 (10%)
were still alive. In female rats, 38/50 (76%) of the
control group and 39/50 (78%) ofthe low dose grouplived to the end ofthe study at 104-106 weeks. The
high dose female rats were terminated at week 91,
at which time 8/50 (16%) were still alive.
In male mice, 13/50 (26%) of the control group,
11/50(22%) ofthe lowdose group, and 18/50 (36%) of
the high dose group lived to the end ofthe study at
week 79. In females, 40/50 (80%) of the control
group and 19/50 (38%) ofthe low dose group lived to
the end of the study at 104-106 weeks. The high
dose female mice were killed at week 91, when 7/50
(14%) were alive.
Other than being chemically associated, the caus-
e(s) of death in the rats and female mice was
undetermined. The principal cause ofearly death in
control and dosed male mice was ascending, suppu-
rative urinarytractinfectionthatresultedinnecrot-
ic, ulcerative lesions around the urethral opening,
chronic or suppurative cystitis (often with urinary
tract obstruction), and ascending suppurative pyelo-
nephritis.
Exposure to 1,2-dibromoethane was also associ-
ated with hepatic necrosis and toxic nephropathy in
rats or either sex, testicular degeneration in male
rats, retinal degeneration in female rats, and epi-
thelial hyperplasia of the respiratory system in
mice.
Carcinomas and adenocarcinomas of the nasal
cavity were observed with significantly increased
incidences (p < 0.001) in high dose rats ofeither sex
relative to controls. The incidences of adenocarci-
nomas and ademonas of the nasal cavity were also
significantly increased (p < 0.001) in low dose rats
of either sex. Adenomatous polyps of the nasal
cavity showed a significantly increased incidence (p
< 0.001) in low dose male rats. The combined
incidence of alveolar/bronchiolar adenomas or car-
cinomas was statistically significant (p < 0.05) for
high dose female rats.
Hemangiosarcomas of the circulatory system
(mainly spleen) and mesotheliomas of the tunica
vaginalis occurred in high dose male rats with
significantly increased incidences (p < 0.001) rela-
tive to controls.
The incidence offibroadenomas of the mammary
gland was significantly elevated (p < 0.001) in
dosed female rats compared to controls.
The incidences of alveolar/bronchiolar carcinoma
and alveolar/bronchiolar adenoma weresignificantly
increased (p < 0.001) in high dose male mice. These
tumors were also increased in high-dose female
mice (p < 0.01 for adenomas and p < 0.001 for
carcinomas).
Hemangiosarcomas occurred in low and high
dose female mice at incidences significantly greater
(p < 0.001) than the incidence ofthe controls. High
dose female mice also had significantly increased
incidences of subcutaneous fibrosarcomas (p <
0.001), ofnasal cavity carcinomas (p < 0.05), and of
mammary gland adenocarcinomas (p < 0.05). Low
dosefemalemicealsoshowed asignificantlyincreased
incidence (p < 0.001) of mammary gland adenocar-
cinomas.
Table 1 catalogs those primary tumor increases
that occurred in rats and Table 2 lists those in mice.
Other tumor increases, some showing a statisti-
cally significant dose-related trend (yet none ofthe
individual dose groups were different than corres-
ponding controls), occurred in male rats (subcuta-
neousfibroma: control3/50, lowdose 6/50, high dose
8/50; salivary gland sarcoma [trend statistic p <
0.05]: 0/49, 1/50, 3/48), in female rats (subcutaneous
fibroma or fibrosarcoma [trend statistic p < 0.01]:
0/50, 0/50, 4/50; mammary gland adenocarcinoma
[trend p < 0.05]: 1/50, 0/50, 4/50), in male mice
(circulatorysystemhemangiomaorhemangiosarcoma
[trend p < 0.01]: 0/45, 0/50, 4/50), andinfemalemice
Table 1. Primary tumor increases in F344 rats exposed to 1,2-dibromoethane by inhalation.
Male Female
Chamber Chamber
Site/Tumor control 10 ppm 40 ppm control 10 ppm 40 ppm
Circulatory system hemangiosarcomaab 0/50 1/50 15/50C 0/50 0/50 5/50d
Lung alveolar/bronchiolar carcinoma or adenomab 1/50 2/50 1/50 0/50 0/48 5/47d
Mammary gland fibroadenomab 0/50 0/50 0/50 4/50 29/50C 24/50c
Nasal cavity all tumorsa,ef 0/50 39/50C 41/50c 1/50 34/50C 43/50C
Tunica vaginalis mesotheliomaa 0/50 7/50g 25/50C - _ _
aDose-related trend for males (p < 0.001).
bDose-related trend for females (p < 0.005).
'Greater than controls (p < 0.001).
dGreater than controls (p < 0.05).
eDose-related trend for females (p < 0.001).
'Adenoma, adenocarcinoma, adenomatous polyp, squamous cellpapilloma, squamous cellcarcinoma, papillary adenoma, carcinoma(in-
dividual tumor incidences are given in reference 17).
gGreater than controls (p < 0.01).
360 CONDENSATION1,2-DIBROMOETHANE (ETHYLENE DIBROMIDE)
Table 2. Primary tumor increases in B6C3F, mice exposed to 1,2-dibromoethane by inhalation.
Male Female
Chamber Chamber
Site/Tumor control 10 ppm 40 ppm control 10 ppm 40 ppm
Circulatory system hemangiosarcomaa 0/45 0/50 2/50 0/50 11/50b 23/50b
Lung alveolar/bronchiolar carcinoma or adenomaa,c 0/41 3/48 23/46b 4/49 11/49d 41/50b
Mammary gland fibroadenoma 0/45 0/50 0/50 2/50 14/50b 8/50d
Nasal cavity all tumorsa"e 0/45 0/50 0/50 0/50 0/50 12/50b
Skin subcutaneous fibrosarcomaa 0/45 0/50 2/50 0/50 5/50d 11/50b
aDose-related trend for females (p < 0.001).
bGreater than controls (p < 0.001).
CDose-related trend for males (p < 0.001).
dGreater than controls (p < 0.05).
eAdenoma, adenomatous polyp, carcinoma, hemangiosarcoma (individual tumor incidences are given in reference 17).
(circulatory system hemangioma [trend p < 0.05]:
0/50, 1/50, 4/50).
Statistically significant (p < 0.05) decreases in
tumor incidence were found for male rats (mononu-
clear cell leukemia: 6/50, 7/50, 1/50; adrenal pheo-
chromocytoma: 4/49, 5/49, 0/48; pituitary gland ade-
noma: 10/45, 7/48, 2/47; interstitial celltumors ofthe
testes: 35/50, 45/50, 10/49), in female rats (all leuke-
mias: 6/50, 7/50, 1/50; pituitary gland adenoma:
21/50, 18/49, 4/45), and infemale mice (lymphoma or
leukemia: 8/50, 7/50, 1/50; pituitary gland adenoma:
8/48, 1/46, 0/40). Except for the decreases in pitu-
itary adenoma in female mice, these decreased
tumor incidences reflect a significantly lower fre-
quency inthe particularhigh dose group. Andthese
lack of tumor responses are likely due to the
decreases in survival observed in these high dose
groups.
Discussion
A carcinogenesis bioassay of 1,2-dibromoethane,
a widely used pesticide, soil and grain fumigant,
and leaded gasoline additive, was conducted by
exposing groups of 50 F344 rats and B6C3F1 mice
of each sex by inhalation to concentrations of 10 or
40 ppm ofthe 1,2-dibromoethane for 78-103 weeks.
Untreated controls consisted of50 rats and 50 mice
of each sex exposed in chambers to ambient air.
Mean body weights ofhigh dose male and female
rats werelowerthanthoseofcorrespondinguntreated
controls throughout the study, and survival in the
same high dose groups was significantly shorter
than that of controls. Mean body weights of high
dose mice were lower than those of corresponding
controls throughout the study, and survival in
dosed females was significantly shorter than that of
controls. Control and dosed male mice had poor
survival, the principal cause of death being an
ascending suppurative urinary tract infection that
was unrelated to compound administration.
Among the observed compound-related nonneo-
plastic lesions were hepatic necrosis and toxic
nephropathy in male and female rats, testicular
degeneration and atrophy in males, and retinal
degeneration in females. A 91-day study by Rowe
et al. (15) reported compound-related nonneoplastic
lesions in some ofthe same organs when rats were
exposed to 1,2-dibromoethane in air at a concentra-
tion of385mg/m3 (50.2ppm) for7hrperday, 5 days
per week. Wong et al. (16) found testicular atrophy
in 90% of male Sprague-Dawley rats exposed to a
combinationofEDB(20ppm)anddisulfiram(0.05%).
Inthe NCI/NTP chronic study (17), inflammation of
the nasal cavity and epithelial hyperplasia of the
respiratory system were diagnosed in dosed male
and female mice. Using the 13-week observations,
Reznik (18) reported finding characteristics of pro-
liferative lesions in the nasal cavities of rats and
mice. Stinson et al. (19) recorded similarfindings in
mice using data from the two-year study (17).
Other lesions observed in male mice were epithelial
hyperplasiaoftheurinarybladderandinflammation
of the prostate gland.
Nitschke et al. (20) exposed groups of ten CDF
(F344) rats to 0, 3, 10, and 40 ppm EDB (five times
per week) for 13 weeks; separate groups were held
for another 13 weeks without additional exposure.
The 3 ppm exposed group exhibited no observable
lesions; the 10 ppm group showed hyperplasia of
the nasal turbinates. Rats exposed to 40 ppm
developed hyperplasia and nonkeratinizing squa-
mous metaplasia of the respiratory epithelium.
After the post exposure period these lesions were
not observed in the rats exposed for the first 13
weeks.
Supernatant ofrat liverhomogenates contains an
361enzyme that catalyzes the reaction between gluta-
thione and 1,2-dibromoethane (21); Watanabe et al.
(22) have calculated that 20 mg 1,2-dibromoe-
thane (by inhalation) would deplete the rat liver of
glutathione.
According to Edwards et al. (23), the small
intestine, liver, kidney, and fat of male RF/Hiraki
rats contained most of the radioactivity 3 hr after
intraperitoneal injection of 1,2-14C-dibromoethane
(40 mg/kg). When rats were given intraperitoneal
injections of 1,2-14C-dibromoethane (4.2 mol) and
killed after 24 hr, the largest amount ofradioactiv-
ity was bound to protein, DNA, and RNA in the
liver and kidney, and intermediate amounts were
found in the lung, testes, stomach, and large and
small intestines. Bromoacetaldehyde, an alkylating
agentidentified asametaboliteof1,2-dibromoethane
in rats, has been suggested to be the compound
involved in the irreversible binding to protein and
nucleic acid (24).
1,2-Dibromoethane has been found to affect liver
microsomes, DNA, and sperm. When liver micro-
somes from B6C3F1 mice and when DNA from
salmon sperm were incubated with 14C-bromoacet-
aldehyde and 14C-bromoethanol, these metabolites
of 1,2-dibromoethane were bound covalently to
protein and DNA to a greater extent than was
1,2-dibromoethane (25). After Nachtomi and Sarma
(21) administered 1,2-dibromoethane insingle doses
of0, 5.0, 7.5, 10, 15, or 22 mg/100 g body weight in
corn oil by gavage to male Wistar rats, liver DNA
of dosed rats sedimented more slowly than that of
untreated rats. Nachtomi and Sarma postulated
that the slower sedimentation rate was caused by
single strand breaks in the DNA. Dose-dependent
increases in hepatic DNA single-strand breaks
were shown by White et al. (26) to occur in male
Swiss-Webster mice treated intraperitoneally with
25-75 mg EDB/kg body weight. More breaks were
detected following preincubation in the alkaline
eluting solution, suggesting (by the authors) that
the DNA strand breaks result, in part, from the
alkali-lability of DNA sites alkylated by EDB. No
evidence was found for EDB-induced DNA-DNA
or DNA-protein cross-linking (26).
In the NCI/NTP inhalation study (17), tumors of
the respiratory tract and tumors of the mammary
gland were found at significantly increased inci-
dences in EDB-dosed rats. Carcinomas, adenoma-
tous polyps, and adenocarcinomas of the nasal
cavity and hemangiosarcomas of the circulatory
system in high dose rats of either sex occurred at
incidences higher than those in the corresponding
controls. Mesotheliomas of the tunica vaginalis in
high dose male rats and mammary gland fibro-
adenomas and the combined incidence of alveo-
lar/bronchiolar carcinomas and adenomas in high
dose female rats all occurred at incidences higher
than those in the corresponding controls.
In mice, as in dosed rats, tumors of the respira-
tory tract, (both sexes), hemangiosarcomas of the
circulatory system (female), and tumors of the
mammarygland (female) were found at significantly
increased incidences. Alveolar/bronchiolar adeno-
mas and alveolar/bronchiolar carcinomas in high
dose male and female mice, and the combined
incidence of carcinomas and adenomas of the nasal
cavity, fibrosarcomas of the subcutaneous tissue,
and hemangiosarcomas ofthe circulatory system in
high dose female mice, occurred at incidences
significantly higher than those in the corresponding
controls.
In a chronic bioassay using Sprague-Dawley rats
exposed by inhalation to 20 ppm EDB alone or in
combination with disulfiram (0.05% diet), Wong et
al. (16) observed aconsiderable decrease in survival
after 12-15 months, and a significant increase in
tumors (EDB: mammary gland, spleen, adrenal
gland, liver, kidney, and subcutaneous tissue; EDB
plusdisulfiram: liver, spleen, kidney, adrenalgland,
thyroid gland, lung, mesentery, and mammary
gland).
Data analyses from a previous gavage study
(6,9,27), conducted in the same laboratory as the
present study, showed increased incidences ofsqua-
mous cell carcinomas of the forestomach in Os-
borne-Mendel rats and B6C3F1 mice ofboth sexes,
hepatocellular carcinomas in female rats, hemangio-
sarcomas (primarily ofthe spleen) in male rats, and
alveolar/bronchiolar adenomas in male and female
mice. According to Van Duuren et al. (28) long-
term (62 weeks) dermal application of EDB to Ha:
ICR Swiss mice caused an increased incidence of
respiratory tract tumors, skin papillomas, and skin
carcinomas.
In conclusion and under the conditions of this
bioassay (17) 1,2-dibromoethane was carcinogenic
for F344 rats, causing increased incidences of
carcinomas, adenocarcinomas, adenomas ofthenasal
cavity, and hemangiosarcomas of the circulatory
system in males and females; mesotheliomas ofthe
tunica vaginalis and adenomatous polyps of the
nasal cavity in males; and fibroadenomas of the
mammary gland and alveolar/bronchiolar adenomas
and carcinomas (combined) in females. 1,2-Dibro-
moethane was carcinogenic for B6C3F1 mice, caus-
ing alveolar/bronchiolar carcinomas and alveolar/
bronchiolar adenomas in males and females; and
hemangiosarcomas ofthe circulatory system, fibro-
sarcomas in the subcutaneous tissue, carcinomas of
the nasal cavity, and adenocarcinomas ofthe mam-
mary gland in females.
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